NASDAQ · Biotechnology

Fresh2 Group Limited (FRES) Stock

$0.85 -23.42% NASDAQ: FRES Healthcare

Fresh2 Group Limited, a biotechnology company established in New York, New York, in 2010, officially adopted its current name in April 2023, having previously been known as AnPac Bio-Medical Science Co., Ltd. The company is primarily engaged in the research, development, promotion, and sale of advanced multi-cancer screening and detection tests within the People's Republic of China, leveraging its proprietary cancer differentiation analysis (CDA) technology and associated devices for corporate and life insurance clients.

Valuation

MetricValue
Price$0.85
Market Cap$2.08M
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio1.17
EPS (TTM)$-106578.00
52-Week High$9.00
52-Week Low$0.73
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE728.57%
ROA-251.78%
ROCE5250.00%
Gross Margin69.21%
Operating Margin-870.20%
Net Margin-846.01%
Debt/Equity-0.90
Current Ratio0.32

Annual Financials (USD)

Metric20182019202020212022
Revenue$10.0M$11.0M$21.0M$18.0M$12.0M
Operating Profit$-44.0M$-89.0M$-95.0M$-112.0M$-105.0M
Net Profit$-42.0M$-101.0M$-80.0M$-119.0M$-102.0M
EPS$-153328.00$-353602.00$-271968.00$-344444.00$-106578.00
Op Margin-425.4%-821.4%-461.1%-623.3%-870.2%

Balance Sheet (USD)

Metric20182019202020212022
Total Assets$53.0M$52.0M$50.0M$67.0M$40.0M
Total Liabilities$75.0M$68.0M$47.0M$66.0M$50.0M
Cash$13.0M$6.0M$3.0M$9.0M$2.0M
Borrowings$29.0M$38.0M$8.0M$34.0M$12.0M

Latest News

Daily – Vickers Top Insider Picks for 07/24/2026 Argus Research · Jul 24, 2026 Tractor Supply Q2 Earnings Call Highlights MarketBeat · Jul 23, 2026 Daily – Vickers Top Insider Picks for 07/23/2026 Argus Research · Jul 23, 2026 Freshpet (FRPT) Outpaces Stock Market Gains: What You Should Know Zacks · Jul 21, 2026 Freshpet, Inc. to Report Second Quarter 2026 Results on Wednesday, August 5, 2026 GlobeNewswire · Jul 15, 2026

Cash Flow (USD)

Metric20182019202020212022
Operating Cash Flow$-32.0M$-48.0M$-56.0M$-71.0M$-55.0M
Investing Cash Flow$-6.0M$-6.0M$-4.0M$-8.0M$-3.0M
Financing Cash Flow$171.0M$-51.0M$-181.0M$56.0M$-11.0M
Net Cash Flow$1.0M$-7.0M$-3.0M$6.0M$-7.0M
Free Cash Flow$-35.0M$-52.0M$-58.0M$-75.0M$-57.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.25
FCF Yield-401.37%
Quick Ratio0.32
Interest Coverage-280.98
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ASLNASLAN Pharmaceuticals Limited $0.60 -14.27% -0.06 $777.12M 0.00%
CUTRCutera, Inc. $0.10 +0.00% -0.01 $1.96M 0.00%
EIGRQEiger BioPharmaceuticals, Inc. $8.50 +6.25% -0.17 $12.59M 0.00%
MTPMidatech Pharma plc $0.29 -18.50% -0.02 $1.98M 0.00%
NTBLNotable Labs, Ltd. $0.25 -27.68% -0.05 $2.39M 0.00%

About Fresh2 Group Limited

Fresh2 Group Limited, a biotechnology company established in New York, New York, in 2010, officially adopted its current name in April 2023, having previously been known as AnPac Bio-Medical Science Co., Ltd. The company is primarily engaged in the research, development, promotion, and sale of advanced multi-cancer screening and detection tests within the People's Republic of China, leveraging its proprietary cancer differentiation analysis (CDA) technology and associated devices for corporate and life insurance clients. Beyond these core diagnostic offerings, Fresh2 Group provides comprehensive physical checkup packages and an array of technology services, including market research, design, software coding, development, and testing. The company also markets genetic testing kits and various skincare products. It owns several fundamental technology platforms and actively participates in further technological innovation and product distribution. Adding a unique dimension to its operations, Fresh2 Group also manages an e-commerce platform that facilitates connections between food suppliers and both supermarket operators and restaurant owners.

Fresh2 Group Limited is headquartered in US.

Fresh2 Group Limited (FRES) stock trades at $0.85 with a market capitalization of $2.08M. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 1.17. Over the past 52 weeks the stock has ranged between $0.73 and $9.00, and currently trades 90.6% below its 52-week high.

On profitability, Fresh2 Group Limited generates a return on equity (ROE) of 728.57% — well above the market average, a sign of a high-quality business, return on capital employed of 5250.00%, an operating margin of -870.20%, a net profit margin of -846.01%.

Official website: fresh2.co

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides